重度氣喘的標靶治療(生物製劑):NPS+(美國)
市場調查報告書
商品編碼
1684123

重度氣喘的標靶治療(生物製劑):NPS+(美國)

NPS+ (US) - Targeted Therapies in Severe Asthma (Biologics)

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

美國的過敏症專家和肺病專家在治療氣喘方面有多種選擇。其中一些選項顯然比其他選項具有更高的忠誠度和滿意度,但為什麼呢?本報告概述了影響醫生選擇的關鍵因素、各主要品牌與競爭藥物的比較以及對美國領先氣喘藥物的見解。

報告內容

  • 依品牌比較 NPS 分數
  • 醫師對特定品牌的忠誠度如何?
  • 能引起醫師共鳴的品牌訊息
  • 影響醫師選擇的主要因素
  • 主要品牌的市場佔有率
  • 主要品牌與競爭對手的比較
  • 因品牌滿意度低而容易轉換的品牌

主要品牌

  • Fasenra
  • Nucala
  • Dupixent
  • Tezspire
  • Cinqair
  • Xolair
簡介目錄

There are various options available to US allergists and pulmonologists treating asthma. Clearly, some of these options achieve greater levels of loyalty and satisfaction than others, but why? What are the key factors driving physician choice, and how does each of the leading brands compare to its competitors? Gain insights into leading asthma therapies in the US.

Key Questions Answered:

  • 1. How do NPS scores by brand compare?
  • 2. How loyal are physicians to specific brands?
  • 3. What brand messages resonate with physicians?
  • 4. What are the key factors driving physician choice?
  • 5. What is the market share of leading brands?
  • 6. How does each of the leading brands compare to its competitors?
  • 7. Which brands are vulnerable to switching due to low brand satisfaction?

Key Brands

  • Fasenra
  • Nucala
  • Dupixent
  • Tezspire
  • Cinqair
  • Xolair

Methodology

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.